InflaRx N.V. (IFRX) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Upstream Bio (UPB) over the past year, gaining 4.1% versus a loss of 76.0%. Upstream Bio is the larger company by market cap ($249.2 million vs $225.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | UPB |
|---|---|---|
| Share price | $1.53 | $4.55 |
| Market cap | $225.47M | $249.21M |
| 1-day change | -1.92% | -1.30% |
| YTD return | +51.49% | -83.24% |
| 1-year return | +4.08% | -75.95% |
| 5-year return | -38.06% | — |
| EPS (TTM) | $-0.58 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $33.68 |
| 52-week low | $0.798 | $4.37 |
| Distance from 52-week high | -48.12% | -86.49% |
| Analyst consensus | none | none |
| Avg. price target upside | +400.65% | +584.40% |
| Average volume | 798.72K | 610.08K |
| Shares outstanding | 147.37M | 54.77M |
| Employees | 65 | 75 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed UPB by 80.0 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Healthcare · Biotechnology · 65 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Healthcare · Biotechnology · 75 employees
IFRX vs UPB FAQ
Which is bigger, InflaRx N.V. or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $249.21M compared with $225.47M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, IFRX or UPB?
IFRX returned +4.08% over the past 12 months, compared with -75.95% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.